SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending amid analyst upgrades and renewed optimism around its robotaxi program, as highlighted by recent test drives. Community discussions revolve around the potential for a gamma squeeze and debate the company's valuation relative to traditional automakers. Some investors are also closely monitoring Wedbush's price target and potential developments with SpaceX.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending after reporting promising preliminary data from its FLAMINGO-01 trial, showing a significant reduction in breast cancer recurrence rates.  The community is actively discussing the implications of these results, especially given the potential for a buyout and the high short interest in the stock.  Despite the positive news, some traders discuss whether the stock is a "short squeeze" and express concern about the trial still needing FDA approval.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to anticipation surrounding upcoming clinical trial data, particularly for RAD101, RAD202, and RAD204, with the community speculating on positive results and potential partnerships. Community members are actively discussing the company's low market capitalization, potential for significant growth, and strategic investment from Lantheus. Some traders are expressing frustration with low volume and recent price action.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending amid community discussions about its low float and potential for a short squeeze, with some traders eyeing a possible breakout. Chatter suggests the stock may be influenced by broader market trends and speculative trading strategies. Others are closely monitoring key price levels, anticipating a volatile trading session.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Fueled by reports of potential federal cannabis reclassification under a Trump executive order, Tilray is trending as investors anticipate regulatory reform, sparking bullish sentiment. The community is actively discussing potential benefits like tax relief and easier access to funding, while also weighing the possibility of a 'sell-the-news' event. With high short interest and comparisons to past cannabis rallies, the stock is experiencing significant volatility as the sector anticipates major regulatory changes.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending after reporting positive Phase 2 trial results for its CAR-T cell therapy in stiff person syndrome, leading to plans for a BLA submission in 1H 2026.  The community is discussing the potential of miv-cel to become the first approved therapy for SPS and the first CAR T treatment for autoimmune disease, while also highlighting the company's strong financial position and acquisition potential. Some are concerned about the niche market affecting sales and stability, while others are excited about the possibility of a double-digit valuation.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power Corp is trending as investors discuss its potential role in powering AI data centers, particularly given the urgent need for power in future hyperscale facilities. Community sentiment is mixed, with some highlighting the company's NRC-certified design as a key advantage, while others express concerns about commercialization, costs, and execution. Discussions also include Fluor's stake monetization and an upcoming shareholder vote that could significantly impact the stock.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as investors react to reports of a potential $7 billion acquisition of cybersecurity firm Armis, with some analysts downgrading the stock. The community is debating whether the company is overvalued, especially given KeyBanc's recent underweight rating and price target. Despite strategic partnerships and AI initiatives, the stock has underperformed this year, leading to discussions about its growth prospects and valuation in the face of increasing competition.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

The AdvisorShares Pure US Cannabis ETF ($MSOS) is surging amid renewed speculation that the federal government may reclassify marijuana, potentially offering tax relief and boosting profitability for cannabis businesses. Community discussions revolve around whether this time is different, with many citing past false starts and the need for confirmed news before fully trusting the rally. The sector-wide move is also drawing attention to specific stocks that could benefit most from the shift.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

Immunome is trending after announcing positive Phase 3 trial results for its desmoid tumor therapy, varegacestat. Community members are discussing the drug's effectiveness, its potential market value, and plans for FDA submission. The stock is experiencing volatility as investors weigh the positive data against profit-taking opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are presently covering the stock, Marketbeat.com...

Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed a "buy" rating and set a $21.00 target price on shares of Ocular Therapeutix in a research report on Tuesday...

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Ocular Therapeutix Inc (NASDAQ: OCUL) stock surged after announcing plans to expedite FDA submission for its wet AMD treatment.read more...

Ocular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Ocular Therapeutix in a report on Monday...

Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year High - Here's Why

Ocular Therapeutix (NASDAQ:OCUL) Hits New 52-Week High - Here's Why...

Ocular Therapeutix (NASDAQ:OCUL) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Ocular Therapeutix from a "hold" rating to a "sell" rating in a report on Saturday...

Ocular Therapeutix (NASDAQ:OCUL) Trading Up 12.3% - What's Next?

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 12.3% - Here's What Happened...

Intech Investment Management LLC Sells 22,361 Shares of Ocular Therapeutix, Inc. $OCUL

Intech Investment Management LLC lessened its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 19.7% during the second quarter, according to the company in its most recent 13F...

Ocular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from HC Wainwright

HC Wainwright restated a "buy" rating and issued a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday...

Ocular Therapeutix (NASDAQ:OCUL) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of Ocular Therapeutix from a "sell" rating to a "hold" rating in a research report on Monday...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

OCUL
Ocular Therapeutix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCUL News

OCULOcular Therapeutix Inc